T cell antigen receptor vaccines for active therapy of T cell malignancies

Sunil A. Reddy, Craig Okada, Carmen Wong, David Bahler, Ronald Levya

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.

Original languageEnglish (US)
Pages (from-to)97-105
Number of pages9
JournalAnnals of the New York Academy of Sciences
Volume941
StatePublished - 2001
Externally publishedYes

Fingerprint

Active Immunotherapy
T-cells
T-Cell Antigen Receptor
Vaccines
T-Lymphocytes
Neoplasms
Mycosis Fungoides
Lymphoproliferative Disorders
Neoplasm Antigens
Immunotherapy
Tumors
Antigens
Vaccine
Cells
Therapy
Therapeutics

Keywords

  • Idiotype
  • Mycosis fungoides
  • T cell malignancies
  • T cell receptor
  • Tumor antigens
  • Vaccine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

T cell antigen receptor vaccines for active therapy of T cell malignancies. / Reddy, Sunil A.; Okada, Craig; Wong, Carmen; Bahler, David; Levya, Ronald.

In: Annals of the New York Academy of Sciences, Vol. 941, 2001, p. 97-105.

Research output: Contribution to journalArticle

Reddy, Sunil A. ; Okada, Craig ; Wong, Carmen ; Bahler, David ; Levya, Ronald. / T cell antigen receptor vaccines for active therapy of T cell malignancies. In: Annals of the New York Academy of Sciences. 2001 ; Vol. 941. pp. 97-105.
@article{759e17fe89e04de4969f96a98635aa2d,
title = "T cell antigen receptor vaccines for active therapy of T cell malignancies",
abstract = "T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.",
keywords = "Idiotype, Mycosis fungoides, T cell malignancies, T cell receptor, Tumor antigens, Vaccine",
author = "Reddy, {Sunil A.} and Craig Okada and Carmen Wong and David Bahler and Ronald Levya",
year = "2001",
language = "English (US)",
volume = "941",
pages = "97--105",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - T cell antigen receptor vaccines for active therapy of T cell malignancies

AU - Reddy, Sunil A.

AU - Okada, Craig

AU - Wong, Carmen

AU - Bahler, David

AU - Levya, Ronald

PY - 2001

Y1 - 2001

N2 - T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.

AB - T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.

KW - Idiotype

KW - Mycosis fungoides

KW - T cell malignancies

KW - T cell receptor

KW - Tumor antigens

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0034813794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034813794&partnerID=8YFLogxK

M3 - Article

C2 - 11594586

AN - SCOPUS:0034813794

VL - 941

SP - 97

EP - 105

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -